Cancer Screening - Danica Wasney, CancerCare Manitoba, Winnipeg, MB
- Discuss which cancers have evidence-based screening recommendations and programs; and
- Discuss controversies surrounding cancer screening at both the patient-specific and population level.
Prostate Cancer - Gerry Mills, Valley Regional Hospital, Kentville, NS
A brief review of pathology and treatment of prostate cancer for oncology pharmacists.
- Give a brief review of pathology & staging of Prostate cancer;
- Review therapies at various stages of disease with a brief review of clinical data for the various treatment modalities;
- Discuss expected outcomes of treatment modalities in terms of response and toxicities; and,
- Review the prevention, monitoring and treatment of adverse effects associated with the various individual treatments.
Gynecological Cancers - Michelle Deschamps, Saskatchewan Cancer Agency, Saskatoon, SK
- Identify the common adjuvant (curative) strategies for early stage ovarian, cervical and endometrial cancers;
- Describe the first line treatment options for advanced ovarian, cervical and endometrial cancers;
- Discuss the role of hormone and targeted therapies in gynecological cancers; and
- Develop symptom management plans for patients undergoing treatment.
Myeloproliferative Neoplasms - Kyla Marien, Tom Baker Cancer Centre, Calgary, AB
- Define the three common non-Philadelphia chromosome myeloproliferative neoplasms: Essential thrombocytosis, Polycythemia Vera, and Myelofibrosis;
- Identify the different signs and symptoms associated with each neoplasm;
- Treatment options in managing symptoms and controlling each disease; and
- Pharmacist’s role in supportive care, patient education, and monitoring.
Bone Marrow Transplant - Nikki Blosser, Tom Baker Cancer Centre, Calgary, AB
- Identify the different types of hematopoietic stem cell transplant and indications for each;
- Describe graft versus host disease (GVHD) and its risk in the post-allogeneic transplant setting;
- Discuss the immunosuppressant medications used to minimize the risk of GVHD;
- Review antimicrobial prophylaxis and the medications used at various intervals post-transplant; and
- Discuss other supportive care measures required in this patient population.
Complementary Medicines and Cancer - Scott Gavura, Cancer Care Ontario, Toronto, ON
- Understand why CAM is popular, and why cancer patients may seek out CAM;
- Understand the evidence base for CAM;
- Understand problems and risk of CAM use in cancer care;
- Understand the clinical outcomes of patients that use CAM; and
- How to talk to patients about CAM.
Cancer Pain Management - Diane Brideau-Laughlin, Horizon Health Network, Moncton, NB
- Understand the concept of total pain;
- Initiate an analgesic regimen;
- Understand the basic principles of analgesic titration;
- Manage common opioid-related adverse events; and
- Switch from one opiate to another.
Immunotherapy Toxicity Management - Tom McFarlane, University of Waterloo, Kitchener, ON
Checkpoint inhibitors are rapidly becoming more prevalent in oncology treatment of various malignancies and have the potential to transform cancer care by conferring long-term survival in scenarios where treatment options have traditionally been very limited. However, these agents carry with them the potential for immune-mediated adverse effects requiring very specific management. These adverse effects have the potential for misdiagnosis and mismanagement, and it is up to us as clinicians to ensure that patients are properly educated about reporting them, and also to keep other members of the patient’s healthcare team apprised of what to do when a patient on checkpoint inhibition presents with toxicity. This presentation will delve into the different adverse effects that patients may experience on checkpoint inhibitor treatment, and give practical examples of how to manage potential toxicity from these agents.
- Understand the mechanistic basis behind the development of adverse effects with checkpoint inhibition;
- Recognize potential adverse effects of treatment with checkpoint inhibitors; and
- Manage adverse effects of checkpoint inhibitors when they occur.
Oncologic Emergencies - Jason Wentzell, The Ottawa Hospital, Ottawa, ON
- Participants will learn about the underlying mechanisms, associated malignancies, characteristic symptoms and appropriate therapeutic management and monitoring of the following oncologic emergencies:
- Tumor lysis syndrome
- Hypercalcemia of malignancy
- Malignant spinal cord compression
- Participants will receive a brief introduction to promote awareness and recognition into how paraneoplastic syndromes and immunotherapy may also contribute on oncologic emergencies